BiotechTube

NPH insulin plus Complete Insulin Orders + Complete Insulin Orders

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperglycemia

Conditions

Hyperglycemia

Trial Timeline

Aug 1, 2010 → Aug 1, 2012

NCT ID
NCT01184014

About NPH insulin plus Complete Insulin Orders + Complete Insulin Orders

NPH insulin plus Complete Insulin Orders + Complete Insulin Orders is a approved stage product being developed by Sanofi for Hyperglycemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01184014. Target conditions include Hyperglycemia.

What happened to similar drugs?

2 of 4 similar drugs in Hyperglycemia were approved

Approved (2) Terminated (2) Active (0)
✅Dapagliflozin + Sliding scale insulinAstraZenecaApproved
✅insulin glargine + insulin glargine + insulin glargineSanofiApproved
❌Human regular insulin + Insulin lispro + Insulin glargineEli LillyPhase 3
❌insulin glargine recombinant + therapeutic insulinSanofiPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01184014ApprovedCompleted

Competing Products

9 competing products in Hyperglycemia

See all competitors
ProductCompanyStageHype Score
Exenatide + InsulinEli LillyPhase 2/3
38
Human regular insulin + Insulin lispro + Insulin glargineEli LillyPhase 3
32
Dapagliflozin + Sliding scale insulinAstraZenecaApproved
43
GLP-1 control + GLP-1 and Exendin(9-39) 300 + saline control + GLP-1 and Exendin(9-39) 600 + GLP-1 and Exendin(9-39) 900 + GLP-1 and Exendin(9-39) 1200MerckPhase 1
29
liraglutide + placeboNovo NordiskPre-clinical
26
Olanzapine + ZiprasidonePfizerPre-clinical
26
insulin glargine + insulin glargine + insulin glargineSanofiApproved
43
Lantus® (insulin glargine)SanofiPhase 1
29
insulin glargine recombinant + therapeutic insulinSanofiPhase 3
32